FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1986290475> ?p ?o ?g. }

• W1986290475 endingPage "258" @default.
• W1986290475 startingPage "258" @default.
• W1986290475 abstract "There are conflicting data regarding the comparative efficacy of mycophenolate mofetil (MMF) versus azathioprine (AZA) as maintenance immunosuppressive agent in kidney transplantation. The data are even less in combination with tacrolimus (TAC) in living donor kidney transplantation. A total of 205 living donor kidney transplants, on TAC-based triple drug immunosuppression were included in the study. A total of 113 patients received AZA and rest 92 were on MMF based protocol. TAC levels were monitored and graft biopsy was done whenever rejection was suspected. The outcomes were evaluated in terms acute rejection (AR) episodes at 1 year, infections, renal function, graft loss, and death between two groups. The study group comprised 163 males (79.5%) and 42 (20.5%) females. The mean age of patients was 42.4±11.8 years in the AZA group and 39.4 ±13.4 in the MMF group (P=0.09). The mean duration of follow-up was 491.7±240.7 and 478.8±334.4 days respectively in the AZA and MMF groups (P=0.75). Thirty-seven of 92 (40.2%) patients in the MMF group and 70/113 (61.9%) patients in the AZA group received IL-2 RAb induction (P=0.002). 32 patients (15.6 %) developed AR within a year. The incidence of AR was similar in patients who received MMF (12/92, 13%) and those who received AZA (20/113, 17.5%), (P=0.36). There was no difference in the incidence of AR in the subgroup of patients who received IL-2 RAb compared to those who did not receive induction in the two groups (5/37 vs. 7/55 in the MMF group and 10/70 vs. 10/43 in the AZA group, P=0.72). The incidence of infections was similar in the two groups (19/92, 20.6% vs. 25/113, 22.1%, P=0.79). Three patients developed CMV disease, of which two were in the MMF group. Graft loss occurred in 7/205 (3.4%) and death in 8/205 (3.9%) patients. Six of eight patients who died had functioning grafts. The rate of graft loss (3/92 vs. 4/113, P=0.97) and death (5/92 vs. 3/113, P=0.27) was similar in two groups. The overall patient survival was 94.5% and death censored graft survival was 97.4%. Cost comparison suggests AZA to be 6-10 times cheaper than MMF. This study suggests that, in tacrolimus-based immunosuppression, azathioprine may be as good as MMF as maintenance immunosuppressive drug in living donor kidney transplantation. It is also a more cost-effective immunosuppression." @default.
• W1986290475 created "2016-06-24" @default.
• W1986290475 creator A5030208277 @default.
• W1986290475 creator A5037155360 @default.
• W1986290475 creator A5044163443 @default.
• W1986290475 creator A5049856218 @default.
• W1986290475 creator A5077044788 @default.
• W1986290475 creator A5082043311 @default.
• W1986290475 creator A5084843107 @default.
• W1986290475 creator A5089507477 @default.
• W1986290475 date "2011-01-01" @default.
• W1986290475 modified "2023-10-13" @default.
• W1986290475 title "Comparison of azathioprine with mycophenolate mofetil in a living donor kidney transplant programme" @default.
• W1986290475 cites W1883629116 @default.
• W1986290475 cites W1991543969 @default.
• W1986290475 cites W1999294805 @default.
• W1986290475 cites W2017163990 @default.
• W1986290475 cites W2025498861 @default.
• W1986290475 cites W2029340370 @default.
• W1986290475 cites W2036523293 @default.
• W1986290475 cites W2044600432 @default.
• W1986290475 cites W2056316390 @default.
• W1986290475 cites W2105918551 @default.
• W1986290475 cites W2117184184 @default.
• W1986290475 cites W2134737353 @default.
• W1986290475 cites W2167078188 @default.
• W1986290475 cites W2167346866 @default.
• W1986290475 cites W2170730772 @default.
• W1986290475 cites W2336236972 @default.
• W1986290475 cites W32301231 @default.
• W1986290475 doi "https://doi.org/10.4103/0971-4065.85483" @default.
• W1986290475 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3193669" @default.
• W1986290475 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22022086" @default.
• W1986290475 hasPublicationYear "2011" @default.
• W1986290475 type Work @default.
• W1986290475 sameAs 1986290475 @default.
• W1986290475 citedByCount "18" @default.
• W1986290475 countsByYear W19862904752013 @default.
• W1986290475 countsByYear W19862904752014 @default.
• W1986290475 countsByYear W19862904752015 @default.
• W1986290475 countsByYear W19862904752017 @default.
• W1986290475 countsByYear W19862904752018 @default.
• W1986290475 countsByYear W19862904752019 @default.
• W1986290475 countsByYear W19862904752020 @default.
• W1986290475 countsByYear W19862904752021 @default.
• W1986290475 countsByYear W19862904752022 @default.
• W1986290475 countsByYear W19862904752023 @default.
• W1986290475 crossrefType "journal-article" @default.
• W1986290475 hasAuthorship W1986290475A5030208277 @default.
• W1986290475 hasAuthorship W1986290475A5037155360 @default.
• W1986290475 hasAuthorship W1986290475A5044163443 @default.
• W1986290475 hasAuthorship W1986290475A5049856218 @default.
• W1986290475 hasAuthorship W1986290475A5077044788 @default.
• W1986290475 hasAuthorship W1986290475A5082043311 @default.
• W1986290475 hasAuthorship W1986290475A5084843107 @default.
• W1986290475 hasAuthorship W1986290475A5089507477 @default.
• W1986290475 hasBestOaLocation W19862904751 @default.
• W1986290475 hasConcept C120665830 @default.
• W1986290475 hasConcept C121332964 @default.
• W1986290475 hasConcept C126322002 @default.
• W1986290475 hasConcept C126894567 @default.
• W1986290475 hasConcept C141071460 @default.
• W1986290475 hasConcept C2776760755 @default.
• W1986290475 hasConcept C2778033501 @default.
• W1986290475 hasConcept C2779134260 @default.
• W1986290475 hasConcept C2780252810 @default.
• W1986290475 hasConcept C2780303639 @default.
• W1986290475 hasConcept C2909675724 @default.
• W1986290475 hasConcept C2909935303 @default.
• W1986290475 hasConcept C2911091166 @default.
• W1986290475 hasConcept C61511704 @default.
• W1986290475 hasConcept C71924100 @default.
• W1986290475 hasConcept C90924648 @default.
• W1986290475 hasConceptScore W1986290475C120665830 @default.
• W1986290475 hasConceptScore W1986290475C121332964 @default.
• W1986290475 hasConceptScore W1986290475C126322002 @default.
• W1986290475 hasConceptScore W1986290475C126894567 @default.
• W1986290475 hasConceptScore W1986290475C141071460 @default.
• W1986290475 hasConceptScore W1986290475C2776760755 @default.
• W1986290475 hasConceptScore W1986290475C2778033501 @default.
• W1986290475 hasConceptScore W1986290475C2779134260 @default.
• W1986290475 hasConceptScore W1986290475C2780252810 @default.
• W1986290475 hasConceptScore W1986290475C2780303639 @default.
• W1986290475 hasConceptScore W1986290475C2909675724 @default.
• W1986290475 hasConceptScore W1986290475C2909935303 @default.
• W1986290475 hasConceptScore W1986290475C2911091166 @default.
• W1986290475 hasConceptScore W1986290475C61511704 @default.
• W1986290475 hasConceptScore W1986290475C71924100 @default.
• W1986290475 hasConceptScore W1986290475C90924648 @default.
• W1986290475 hasIssue "4" @default.
• W1986290475 hasLocation W19862904751 @default.
• W1986290475 hasLocation W19862904752 @default.
• W1986290475 hasLocation W19862904753 @default.
• W1986290475 hasLocation W19862904754 @default.
• W1986290475 hasOpenAccess W1986290475 @default.
• W1986290475 hasPrimaryLocation W19862904751 @default.
• W1986290475 hasRelatedWork W1979880594 @default.
• W1986290475 hasRelatedWork W1992117911 @default.

• next